Peru seizes 4 tons of black market mercury bound for illegal gold mines
The mercury had been passed off as a container of crushed rock, but Peru's customs agency SUNAT said an analysis revealed that the material had been laced with mercury, a toxic metal that is subject to strict environmental controls.
"We could determine that mercury was being transported in its natural state, camouflaged in shipments of gravel," SUNAT said in a statement. The cargo was detected at the Callao port and came from Mexico, it added.
The seizure appears to be the largest on record in the Amazon region of South America where illegal gold mining is widespread, according to a review of past seizures by the Environmental Investigation Agency (EIA), a Washington-based advocacy nonprofit.
Until now, the biggest known shipment in the region, about a decade ago, was only half the size, according to the EIA.
The latest discovery comes as gold prices have soared in recent months, as global trade uncertainty has made gold particularly attractive for investors. Gold prices are up 28.5% so far this year and hit a record high of $3,500 per troy ounce in April. The frenzy for gold has led to deadly encounters from West Africa to Peru.
The EIA said it alerted Peruvian authorities to the shipment during its research into illicit mercury shipments from Mexico to Bolivia, Colombia and Peru, where miners use mercury to leach gold from sediment of the Amazon riverbanks.
It said higher mercury prices were driving illegal mercury production in Mexico, with a particular spike since the start of this year as traffickers paid a record $330 per kilogram.
"According to traffickers, gold miners' demand for mercury has driven the sophisticated operation and made it profitable," the EIA said in a report released on Thursday.
It said its investigation showed that 200 tons of mercury were smuggled from Mexico to Bolivia, Colombia and Peru between April 2019 and June 2025, accounting for a conservative estimate of $8 billion in illegal gold.
Peruvian officials did not address the role of the EIA in the discovery of the mercury-laced gravel from Mexico.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
13 minutes ago
- Reuters
Regeneron beats second-quarter results estimates on Dupixent sales boost
Aug 1 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its shares up nearly 3% in premarket trading. Investors have set a high bar for Regeneron and French partner Sanofi's ( opens new tab Dupixent, one of the U.S. drugmaker's growth drivers, especially after it received approval to treat a common lung condition called chronic obstructive pulmonary disease last year. Sales of the anti-inflammatory drug rose 22% to $4.34 billion, compared with an estimate of $4.14 billion. The Tarrytown, New York-based company is also banking its cancer treatment, Libtayo, to drive future growth at a time when its blockbuster eye disease drug Eylea has been grappling with stiff competition from cheaper versions and rival drugs such as Roche's (ROG.S), opens new tab Vabysmo. U.S. sales of Eylea, jointly developed with Bayer AG ( opens new tab, fell 25% to $1.15 billion, including $393 million from the higher, 8-milligram dose version of the drug. Analysts were expecting $2.17 billion in total Eylea sales. Roche reported Vabysmo sales of 2.07 billion Swiss francs ($2.54 billion) last week, slightly below analyst expectations. On an adjusted basis, Regeneron earned a quarterly profit of $12.89 per share, compared with analysts' average expectation of $8.44 per share, according to data compiled by LSEG. The company's total revenue for the quarter was $3.68 billion, above an expectation of $3.28 billion. Skin cancer drug Libtayo brought in sales of $377 million, versus analysts' average estimate of $338.75 million. Separately, Regeneron is among 17 drugmakers that have received a letter from the U.S. President Donald Trump asking them to slash U.S. prescription drug prices to match overseas rates. ($1 = 0.8161 Swiss francs)
Reuters
16 minutes ago
- Reuters
India's NSE settles with regulator for $4.6 million over data sharing case
Aug 1 (Reuters) - India's largest bourse operator, National Stock Exchange of India, has settled a matter involving the sharing of confidential information of listed companies indirectly to a third-party vendor with the markets regulator for 403.5 million rupees ($4.6 million), the regulator said on Friday. ($1 = 87.4580 Indian rupees)
Reuters
16 minutes ago
- Reuters
Canada's Imperial Oil posts fall in quarterly profit on lower crude prices
Aug 1 (Reuters) - Canadian oil producer Imperial Oil ( opens new tab posted a fall in second-quarter profit on Friday, hurt by lower crude prices and a decline in refinery throughput. Benchmark Brent crude prices were lower during the April-June quarter compared to a year earlier, pressured by weak global demand, market volatility due to tariffs and increased oil supply from OPEC+. The company's refinery throughput volumes fell to 376,000 barrels per day during the second quarter from 387,000 bpd a year ago. The Calgary, Alberta-based company said its net income fell to C$949 million ($684.31 million), or C$1.86 per share, in the quarter ended March 31, from C$1.13 billion, or C$2.11 per share, a year earlier. ($1 = 1.3868 Canadian dollars)
